SDGR: ACV momentum and a Structure milestone lifted FY26 guidance amid expanding hosted software adoption

What happened

Schrödinger reported third-quarter revenue growth of 19%, rising annual contract value (ACV), meaning the yearly value of customer contracts, across customer types, and accelerating adoption of hosted software. It increased its fiscal-year ACV and drug discovery guidance, citing commercial momentum and a Structure milestone.

Confirmed

Global impact / market context

Revenue growth and rising contract value point to stronger customer demand, while hosted software adoption may support ongoing sales from software access. Higher guidance indicates management expects the momentum to continue; the Structure milestone also supports its drug discovery outlook, though the article gives no financial details.

Analyst inference

The update combines software demand signals with progress in drug discovery, so investors may assess whether both can sustain growth. Hosted adoption could support recurring revenue, while ACV growth indicates contracted business, but the article gives no guidance figures or breakdown of the milestone’s financial contribution.

Analyst inference

What to watch

1. Check later reports for whether revenue and ACV continue rising across customer types and whether hosted software adoption remains strong, as the article provides no further figures. Analyst inference
2. Look for the updated ACV and drug discovery guidance targets; the article confirms increases but does not state the revised figures or the time period covered. Confirmed
3. Seek details on the Structure milestone and whether it advances drug discovery or changes related revenue and costs, since the article does not explain its financial effect. Analyst inference

Evidence

• Original source link unavailable